About Delcath Systems Inc
- Industry: Health Care
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://delcath.com/
Frequently Asked Questions
What is the 52-week range for DCTH?
The 52-week high is $17.42 and the 52-week low is $8.12.
What is the P/E ratio for DCTH?
The Price to Earnings (P/E) ratio is 984.87.
What is the dividend yield for DCTH?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 0.46%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 0.56%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.21.
Analyst Recommendation Trends
Wall Street analyst consensus for DCTH over the last few months:
Latest DCTH News
Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year?
Here is how CryoPort, Inc. (CYRX) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.
3 Emerging Biotech Stocks With Significant Upside Potential
Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.
Teleflex (TFX) Soars 4.4%: Is Further Upside Left in the Stock?
Teleflex (TFX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains?
Veracyte (VCYT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Are Medical Stocks Lagging Delcath Systems (DCTH) This Year?
Here is how Delcath Systems, Inc. (DCTH) and Encompass Health (EHC) have performed compared to their sector so far this year.
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y., September 11, 2026--Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to four individuals whose employment commenced in either July 2026 or August 2026.
Delcath’s (DCTH) Liver Cancer Device Keeps Growing, But At A Cost
On August 6, Delcath Systems (NASDAQ:DCTH) reported second-quarter results that showed the company selling more of its liver cancer treatment than ever, even as the cost of running the business climbed just as fast. The interventional oncology company posted total revenue of $29.1 million, up from $24.2 million a year earlier, and used the report […]
Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services
EuroDry, RCM Technologies, Assembly Biosciences, Delcath Systems and National Energy Services show strong price momentum after August's market gains.
Keep Portfolio Volatility in Check With VLO, PBF, FET & DCTH
VLO, PBF, FET and DCTH screen as low-beta picks as volatility rises, backed by refining, energy-equipment and liver-cancer growth drivers.
5 Stocks With Recent Price Strength Buoyed by a Strong August
EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by improving earnings expectations.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-05-13 | Aharon Gil | +22,500 | - | - |
| 2026-05-13 | Sylvester John Richard | +22,500 | - | - |
| 2026-05-13 | Martell Bridget A | +22,500 | - | - |
| 2026-05-13 | SALAMON STEVEN A J | +22,500 | - | - |
| 2026-05-13 | CZEREPAK ELIZABETH | +22,500 | - | - |
| 2026-03-06 | Pennell Sandra | +5,533 | $9.04 | $50,018 |
| 2026-03-02 | MICHEL GERARD J | +11,200 | $8.9562 | $100,309 |
| 2026-02-17 | Rook Martha S. | +28,250 | - | - |
| 2026-02-17 | Rook Martha S. | +56,500 | - | - |
| 2026-02-17 | Hoffman David L. | +28,250 | - | - |
| 2026-02-17 | Hoffman David L. | +56,500 | - | - |
| 2026-02-17 | Muir Kevin | +28,250 | - | - |
| 2026-02-17 | Muir Kevin | +56,500 | - | - |
| 2026-02-17 | Pennell Sandra | +28,250 | - | - |
| 2026-02-17 | Pennell Sandra | +56,500 | - | - |
| 2026-02-17 | Vukovic Vojo | +28,250 | - | - |
| 2026-02-17 | Vukovic Vojo | +56,500 | - | - |
| 2026-02-17 | MICHEL GERARD J | +97,500 | - | - |
| 2026-02-17 | MICHEL GERARD J | +195,000 | - | - |
| 2025-11-21 | Sylvester John Richard | +4,386 | $8.89 | $38,992 |
| 2025-11-11 | MICHEL GERARD J | +11,500 | $8.526 | $98,049 |